Jacobs Levy Equity Management Portfolio holdings
Jacobs Levy Equity Management manages U.S. stock portfolios, and its owners Bruce Jacobs and Ken Levy pioneered a research method called disentangling. The firm was founded in 1986, and Jacobs and Levy spent more than three years studying market inefficiencies in U.S. stocks before taking on client money in 1990. Disentangling examines many factors that move stock prices at once, to isolate the separate effect of each, and the firm blends it with behavioral finance theory and human judgment. It runs long-only and long/short portfolios across large and small companies, including versions that hold about 130% or 150% of capital in long positions and 30% or 50% in short ones. Its clients are institutions such as pension plans, endowments, foundations and sovereign wealth funds.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
KLA
KLAC
|
+$325M |
| 2 |
CrowdStrike
CRWD
|
+$225M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$186M |
| 4 |
Sandisk
SNDK
|
+$155M |
| 5 |
Sysco
SYY
|
+$147M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qualcomm
QCOM
|
+$418M |
| 2 |
ServiceNow
NOW
|
+$262M |
| 3 |
Apple
AAPL
|
+$260M |
| 4 |
Masco
MAS
|
+$163M |
| 5 |
Roku
ROKU
|
+$139M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.14% |
| 2 | Financials | 13.01% |
| 3 | Consumer Discretionary | 12.82% |
| 4 | Industrials | 11.2% |
| 5 | Healthcare | 10.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
901
WESCO International
WCC
$15.7B
| $234K | ﹤0.01% |
+678
| New | +$230K |
2026 Q2
0 quarters
|
|
902
Nkarta
NKTX
$85.2M
| $234K | ﹤0.01% |
+82,658
| New | +$233K |
2026 Q2
0 quarters
|
|
903
Crawford & Co Class A
CRD.A
$568M
| $232K | ﹤0.01% |
20,605
+6,820
| +49% | +$72.5K |
2025 Q1
5 quarters
|
|
904
SkinHealth Systems
SKIN
$106M
| $227K | ﹤0.01% |
16,369
-809
| -5% | -$12.4K |
2024 Q1
9 quarters
|
|
905
Intrepid Potash
IPI
$440M
| $219K | ﹤0.01% |
6,693
-1,529
| -19% | -$58.2K |
2025 Q3
3 quarters
|
|
906
Janux Therapeutics
JANX
$696M
| $219K | ﹤0.01% |
+14,238
| New | +$206K |
2026 Q2
0 quarters
|
|
907
Purple Innovation
PRPL
$5.93M
| $217K | ﹤0.01% |
24,327
| – | – |
2025 Q3
3 quarters
|
|
908
Ford
F
$47.6B
| $214K | ﹤0.01% |
+15,415
| New | +$208K |
2026 Q2
0 quarters
|
|
909
Netflix
NFLX
$255B
| $206K | ﹤0.01% |
2,892
-553,090
| -99% | -$48.7M |
2022 Q2
16 quarters
|
|
910
Macy's
M
$6.45B
| $203K | ﹤0.01% |
+8,599
| New | +$180K |
2026 Q2
0 quarters
|
|
911
QuantumScape Corp
QS
$2.28B
| $195K | ﹤0.01% |
+25,752
| New | +$193K |
2026 Q2
0 quarters
|
|
912
Metagenomi Therapeutics
MGX
$26.2M
| $190K | ﹤0.01% |
160,000
-222,153
| -58% | -$297K |
2026 Q1
1 quarter
|
|
913
First Northwest Bancorp
FNWB
$93M
| $183K | ﹤0.01% |
16,897
-37
| -0.2% | -$369 |
2025 Q4
2 quarters
|
|
914
Orion Office REIT
ONL
$149M
| $182K | ﹤0.01% |
62,914
-13,388
| -18% | -$36.7K |
2023 Q4
10 quarters
|
|
915
Aimco
AIV
$212M
| $181K | ﹤0.01% |
60,990
-11,177
| -15% | -$42.8K |
2026 Q1
1 quarter
|
|
916
Net Lease Office Properties
NLOP
$141M
| $154K | ﹤0.01% |
13,867
| – | – |
2025 Q3
3 quarters
|
|
917
ADC Therapeutics
ADCT
$188M
| $151K | ﹤0.01% |
+141,344
| New | +$412K |
2026 Q2
0 quarters
|
|
918
Zevia
ZVIA
$78M
| $130K | ﹤0.01% |
79,488
-214,401
| -73% | -$291K |
2024 Q4
6 quarters
|
|
919
Conduent
CNDT
$195M
| $125K | ﹤0.01% |
85,346
-1,045,679
| -92% | -$1.62M |
2023 Q2
12 quarters
|
|
920
C4 Therapeutics
CCCC
$362M
| $117K | ﹤0.01% |
25,111
-239,509
| -91% | -$819K |
2026 Q1
1 quarter
|
|
921
Silvercrest Asset Management
SAMG
$87.8M
| $116K | ﹤0.01% |
11,476
-1,464
| -11% | -$17.8K |
2026 Q1
1 quarter
|
|
922
JELD-WEN Holding
JELD
$81.2M
| $114K | ﹤0.01% |
76,202
-1,817,799
| -96% | -$2.8M |
2024 Q4
6 quarters
|
|
923
Chegg
CHGG
$63.9M
| $109K | ﹤0.01% |
107,598
-363,771
| -77% | -$399K |
2022 Q1
17 quarters
|
|
924
PMV Pharmaceuticals
PMVP
$95.9M
| $94.5K | ﹤0.01% |
70,504
-109,369
| -61% | -$140K |
2025 Q3
3 quarters
|
|
925
LENZ Therapeutics
LENZ
$130M
| $91.2K | ﹤0.01% |
16,061
-100,950
| -86% | -$814K |
2025 Q4
2 quarters
|
|
Similar funds
Jacobs Levy Equity Management's Q2 2026 Portfolio in Review
As of Q2 2026, Jacobs Levy Equity Management held 1,111 positions worth $27.8B, up 17% from $23.8B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Jacobs Levy Equity Management's Q2 2026 filing shows 158 new, 319 increased, 438 reduced and 177 closed positions. Its largest new stake was Sysco: 1,938,184 shares worth $162M. The largest sale was Qualcomm, an estimated $418M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 31% a quarter earlier, followed by Financials and Consumer Discretionary.
- Jacobs Levy Equity Management's largest Q2 2026 buy was Sysco: 1,938,184 shares worth $162M.
- Jacobs Levy Equity Management added most to KLA in Q2 2026, an estimated $325M increase.
- Jacobs Levy Equity Management's biggest Q2 2026 reduction was Qualcomm, cutting an estimated $418M.
- Jacobs Levy Equity Management fully exited Roku in Q2 2026, selling an estimated $139M.
- Jacobs Levy Equity Management's ten largest holdings make up 28% of its $27.8B portfolio in Q2 2026.
- Jacobs Levy Equity Management opened 158 new positions and closed 177 in Q2 2026.
- Jacobs Levy Equity Management's portfolio value rose 17% quarter-over-quarter to $27.8B.
Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.